Nanobiotix Outlook: Mixed Signals Amid Volatile Market Conditions

Market SnapshotTakeaway: Nanobiotix (NBTX.O) shows a weak technical outlook with bearish signals dominating, while recent price trends show a slight rise of 0.54%.

News Highlights

Recent news affecting the biotech sector includes: U.S. vaccine policy changes: The Department of Health and Human Services under Secretary Robert F. Kennedy Jr. has updated its approach to vaccine approvals, which could impact companies like Nanobiotix in the long term. Bio-Techne receives Overweight rating: Wells Fargo upgraded Bio-Techne with a $59 price target, signaling renewed interest in biotech firms. This might indirectly influence investor sentiment toward companies like Nanobiotix. Crypto ETF news: REX Shares filed for Ethereum and Solana ETFs, showing a broader market appetite for innovation. While unrelated to biotech, it highlights ongoing capital shifts in tech-related assets.

Analyst Views & Fundamentals

Average rating score: 5.00 (simple mean).

Weighted rating score: 3.47 (based on historical performance).

Analyst rating consistency: There are differences in analyst views, but the recent single rating from Guggenheim is a "Strong Buy" with a 100.0% historical win rate.

Price trend alignment: The current price is rising, which aligns with the weighted expectations being relatively neutral.

Key fundamental factors:

Revenue-to-Market Value (Revenue-MV): -17.84% (internal diagnostic score: 2.00).

Price-to-Cash Flow (PCF): 8,944.79 (internal diagnostic score: 4.00).

Price-to-Sales (PS): 1,324.50 (internal diagnostic score: 3.00).

Gross Profit Margin (GPM): 20.45% (internal diagnostic score: 1.00).

Gross Margin to Average Revenue (GMAR): 100.00% (internal diagnostic score: 3.00).

Asset-to-Market Value (Asset-MV): -1.60% (internal diagnostic score: 2.00).

Cash-to-Market Value (Cash-MV): -21.59% (internal diagnostic score: 2.00).

Money-Flow Trends

Big-money vs. retail flows: Nanobiotix is currently experiencing negative money flows across all categories:

Small investors: -48.31% inflow ratio (trend: negative).

Medium investors: -49.58% inflow ratio (trend: negative).

Large and extra-large investors: -49.76% and -49.86% inflow ratios respectively (both trends: negative).

The fund-flow score is 7.91 (internal diagnostic score: good), indicating that, despite the negative trend, there is still some inflow of capital into the stock.

Key Technical Signals

Internal diagnostic scores (0-10) for recent technical indicators:

Long Lower Shadow: 2.67 (bearish bias).

MACD Death Cross: 1.00 (bearish bias).

Piercing Pattern: 1.00 (bearish bias).

Recent chart patterns (by date):

2025-11-26: Long Lower Shadow and MACD Death Cross (both bearish signals).

2025-11-21: MACD Death Cross (bearish signal).

Key insights: Technical indicators show the market in a volatile state, and the price direction is unclear. Bearish signals (3) clearly dominate over bullish ones (0).

Conclusion

With a weak technical outlook, bearish signals dominating, and mixed analyst ratings, Nanobiotix is in a cautious zone. While the stock has seen a slight rise recently, the overall momentum is weak. Investors might want to consider waiting for a pull-back or look for a clearer breakout before committing. Always use caution in volatile biotech sectors where technical and fundamental signals can change rapidly.